Bio Historical Financial Ratios
BIO-B Stock | USD 336.00 3.36 0.99% |
Bio Rad is presently reporting on over 108 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 2.15 or Days Sales Outstanding of 87.31 will help investors to properly organize and evaluate Bio Rad Laboratories financial condition quickly.
Bio |
About Bio Financial Ratios Analysis
Bio Rad LaboratoriesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Bio Rad investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Bio financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Bio Rad history.
Bio Rad Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Bio Rad Laboratories stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Bio Rad sales, a figure that is much harder to manipulate than other Bio Rad Laboratories multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Ev To Operating Cash Flow
A valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows.Most ratios from Bio Rad's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Bio Rad Laboratories current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At present, Bio Rad's Price To Sales Ratio is projected to slightly grow based on the last few years of reporting. The current year's PTB Ratio is expected to grow to 2.15, whereas ROIC is forecasted to decline to 0.03.
2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 52.9 | 64.43 | 66.82 | 87.31 | PTB Ratio | 1.65 | 1.3 | 1.08 | 2.15 |
Bio Rad fundamentals Correlations
Click cells to compare fundamentals
Bio Rad Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bio Rad fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Price To Sales Ratio | 4.78 | 6.82 | 7.71 | 4.47 | 3.53 | 3.71 | |
Ptb Ratio | 1.92 | 1.76 | 1.65 | 1.3 | 1.08 | 2.15 | |
Days Sales Outstanding | 62.0 | 60.14 | 52.9 | 64.43 | 66.82 | 87.31 | |
Book Value Per Share | 192.84 | 331.9 | 458.15 | 322.82 | 299.26 | 314.22 | |
Free Cash Flow Yield | 0.0325 | 0.0275 | 0.0238 | 0.006411 | 0.0231 | 0.0243 | |
Operating Cash Flow Per Share | 15.34 | 19.33 | 22.01 | 6.53 | 12.84 | 13.48 | |
Stock Based Compensation To Revenue | 0.0154 | 0.0163 | 0.0175 | 0.0217 | 0.0229 | 0.0241 | |
Capex To Depreciation | 0.73 | 0.72 | 0.9 | 0.83 | 0.96 | 1.4 | |
Pb Ratio | 1.92 | 1.76 | 1.65 | 1.3 | 1.08 | 2.15 | |
Ev To Sales | 4.68 | 6.56 | 7.55 | 4.74 | 3.91 | 4.1 | |
Free Cash Flow Per Share | 12.04 | 16.0 | 17.96 | 2.7 | 7.47 | 7.85 | |
Roic | 0.0289 | 0.0323 | 0.0279 | 0.0344 | 0.0276 | 0.0262 | |
Net Income Per Share | 58.93 | 128.13 | 142.61 | (121.79) | (21.82) | (20.73) | |
Days Of Inventory On Hand | 191.73 | 205.02 | 162.94 | 212.61 | 229.76 | 148.82 | |
Payables Turnover | 9.86 | 7.94 | 9.03 | 9.14 | 8.57 | 5.69 | |
Research And Ddevelopement To Revenue | 0.12 | 0.087 | 0.0877 | 0.089 | 0.093 | 0.0917 | |
Capex To Revenue | 0.0426 | 0.0389 | 0.0413 | 0.0407 | 0.0587 | 0.0697 | |
Cash Per Share | 37.54 | 33.48 | 29.35 | 60.31 | 55.03 | 57.78 | |
Pocfratio | 24.12 | 30.16 | 34.33 | 64.41 | 25.15 | 15.18 | |
Interest Coverage | 9.81 | 18.8 | 315.56 | 12.66 | 7.4 | 7.03 | |
Capex To Operating Cash Flow | 0.45 | 0.22 | 0.17 | 0.18 | 0.59 | 0.42 | |
Pfcf Ratio | 30.73 | 36.42 | 42.07 | 155.99 | 43.21 | 45.37 | |
Days Payables Outstanding | 37.04 | 45.95 | 40.42 | 39.91 | 42.57 | 58.92 | |
Income Quality | 0.79 | 0.26 | 0.15 | (0.0536) | (0.59) | (0.56) | |
Roe | 0.0899 | 0.31 | 0.39 | (0.38) | (0.0729) | (0.0693) | |
Ev To Operating Cash Flow | 23.63 | 29.04 | 33.63 | 68.34 | 27.82 | 17.4 | |
Pe Ratio | 6.28 | 4.55 | 5.3 | (3.45) | (14.8) | (14.06) | |
Return On Tangible Assets | 0.23 | 0.31 | 0.25 | (0.28) | (0.0551) | (0.0524) | |
Ev To Free Cash Flow | 30.11 | 35.06 | 41.22 | 165.5 | 47.8 | 50.19 | |
Earnings Yield | 0.16 | 0.22 | 0.19 | (0.29) | (0.0676) | (0.0642) | |
Intangibles To Total Assets | 0.0512 | 0.0379 | 0.0338 | 0.0547 | 0.0597 | 0.0567 | |
Net Debt To E B I T D A | (0.0898) | (0.13) | (0.0817) | (0.17) | (1.65) | (1.56) | |
Current Ratio | 2.41 | 3.39 | 2.92 | 5.55 | 5.83 | 6.12 | |
Tangible Book Value Per Share | 179.12 | 315.39 | 438.0 | 298.02 | 274.13 | 287.84 | |
Receivables Turnover | 5.89 | 6.07 | 6.9 | 5.67 | 5.46 | 3.78 | |
Graham Number | 505.67 | 978.19 | 1.2K | 940.55 | 383.3 | 402.46 | |
Shareholders Equity Per Share | 192.84 | 331.9 | 458.15 | 322.82 | 299.26 | 314.22 | |
Debt To Equity | 0.0744 | 2.63E-4 | 8.05E-4 | 0.12 | 0.14 | 0.13 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Bio Rad Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Rad's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Rad Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Rad Laboratories Stock:Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.